What is Oxular?
Oxular operates at the forefront of medical innovation, specifically targeting the complex landscape of retinal diseases. The company distinguishes itself through a dual-pronged approach: the development of proprietary drug formulations and the engineering of sophisticated ocular administration technologies. This integrated strategy is designed to enhance the efficacy and safety of treatments for conditions that have historically proven difficult to manage. By optimizing how therapeutic agents are delivered to the eye, Oxular aims to improve patient outcomes and establish new standards of care within the pharmaceutical and biotech sectors.
How much funding has Oxular raised?
Oxular has raised a total of $37M across 1 funding round:
Other Financing Round
$37M
Other Financing Round (2021): $37M with participation from V-Bio Ventures, NeoMed Management, Forbion, and The IP Group
Key Investors in Oxular
V-Bio Ventures
A life science venture capital firm that co-creates and invests in early- to mid-stage companies, focusing on therapeutics with high growth potential.
NeoMed Management
An international venture capital firm exclusively focused on the healthcare industry, investing in emerging companies across the pharmaceutical, medical device, and diagnostics sectors.
Forbion
A leading European life sciences venture capital firm that invests in companies developing high-impact medical innovations.
What's next for Oxular?
With the support of its latest financing round, Oxular is poised to advance its lead candidates into more mature stages of clinical evaluation. The strategic roadmap likely involves expanding its intellectual property portfolio and strengthening its operational infrastructure to support multi-site clinical trials. As the company moves forward, the focus will remain on validating its ocular delivery systems against existing therapeutic benchmarks. Given the high-growth potential of the retinal therapeutics market, Oxular is expected to leverage its current momentum to attract further institutional interest and potentially explore strategic partnerships that could facilitate the commercialization of its proprietary technologies.
See full Oxular company page
